Diagnosis of chronic fatigue diseases using detection antibodies directed against a β-adrenergic receptor
OwnerHarald Heidecke, Kai Schulze-Forster +1inventors
InventorsHarald Heidecke, Kai Schulze-Forster, Carmen Scheibenbogen
Life of this patent
Estimating the term…
Abstract
The application relates to a method for diagnosis of a chronic fatigue disease, e.g. CFS or CRF, comprising the step of determining the presence or absence of antibodies directed against β-adrenergic receptor in a sample of the subject to be diagnosed, wherein the presence of antibodies directed against β-adrenergic receptor is indicative of the chronic fatigue disease in said subject. Furthermore, the application relates to kits comprising β-adrenergic receptor or an antigenic peptide thereof and the use of β-adrenergic receptor or an antigenic peptide thereof for the diagnosis of a chronic fatigue disease.
Claims11
A method for detecting an autoantibody that binds to one or more β-adrenergic receptors, the method comprising:
- providing a sample from a mammal selected from the group consisting of blood, serum, plasma, cerebrospinal fluid, saliva, urine, sputum, and pleural effusion;
- detecting in said sample an autoantibody that binds to one or more β-adrenergic receptors selected from the group consisting of β1-adrenergic receptor, β2-adrenergic receptor, and β3-adrenergic receptor;
- determining the level of the autoantibody in said sample;
- detecting, in control samples obtained from mammals without a chronic fatigue disease or with depression, an autoantibody that binds to one or more β-adrenergic receptors selected from the group consisting of β1-adrenergic receptor, β2-adrenergic receptor, and β3-adrenergic receptor;
- determining the 90th percentile of the control autoantibody level in said control samples;
- and
- determining whether the determined autoantibody level is greater than the 90th percentile of the control autoantibody level.
Dependencies are inferred from the claim text.